---
schema_version: "secwatch.filing_event.v1"
accession: "0001062993-25-012533"
form_type: "8-K/A"
ticker: "MDCX"
cik: "0001997296"
company_name: "Medicus Pharma Ltd."
filed_at: "2025-07-03T23:59:59+00:00"
generated_at: "2026-05-18T09:31:48.862564+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "medium"
source: SEC EDGAR
---

# Medicus Pharma signs share exchange agreement to acquire Antev Limited

## Summary
- Agreement to acquire all Antev Shares; Antev becomes wholly-owned subsidiary of Medicus.
- Consideration includes Purchaser Shares (Consideration Shares) and Contingent Consideration tied to milestones.
- Antev's lead candidate Teverelix (for acute urinary retention) referenced in forward-looking statements.
- Closing expected 3 Business Days after conditions satisfied; drag-along provisions apply for all shareholders.

## SEC filing metadata
- accession: 0001062993-25-012533
- form_type: 8-K/A
- ticker: MDCX
- cik: 0001997296
- company_name: Medicus Pharma Ltd.
- filed_at: 2025-07-03T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: medium
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1997296/000106299325012533/0001062993-25-012533-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1997296/000106299325012533/form8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001062993-25-012533
- JSON: https://secwatch.observer/filing/0001062993-25-012533.json
- Plain text: https://secwatch.observer/filing/0001062993-25-012533.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.